News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
759,714 Results
Type
Article (54923)
Company Profile (486)
Press Release (704305)
Section
Business (219773)
Career Advice (2883)
Deals (37924)
Drug Delivery (120)
Drug Development (87364)
Employer Resources (182)
FDA (17300)
Job Trends (16214)
News (373283)
Policy (36208)
Tag
Academia (2906)
Alliances (53871)
Alzheimer's disease (1414)
Approvals (17255)
Artificial intelligence (232)
Bankruptcy (387)
Best Places to Work (12335)
Biotechnology (345)
Breast cancer (241)
Cancer (1826)
Cardiovascular disease (146)
Career advice (2417)
CAR-T (134)
Cell therapy (387)
Clinical research (70066)
Collaboration (717)
Compensation (376)
COVID-19 (2793)
C-suite (174)
Data (1669)
Diabetes (229)
Diagnostics (6671)
Earnings (89327)
Employer resources (158)
Events (120602)
Executive appointments (599)
FDA (18241)
Funding (641)
Gene therapy (278)
GLP-1 (750)
Government (4851)
Healthcare (20224)
Infectious disease (2912)
Inflammatory bowel disease (134)
Interviews (553)
IPO (17222)
Job creations (4367)
Job search strategy (2001)
Layoffs (500)
Legal (8969)
Lung cancer (274)
Manufacturing (258)
Medical device (14008)
Medtech (14013)
Mergers & acquisitions (21065)
Metabolic disorders (618)
Neuroscience (1867)
NextGen: Class of 2025 (7283)
Non-profit (4908)
Northern California (2140)
Obesity (345)
Opinion (247)
Patents (173)
People (62381)
Phase I (21759)
Phase II (30732)
Phase III (22969)
Pipeline (739)
Postmarket research (2988)
Preclinical (9336)
Radiopharmaceuticals (261)
Rare diseases (357)
Real estate (6630)
Regulatory (24269)
Research institute (2584)
Resumes & cover letters (455)
Southern California (1845)
Startups (3967)
United States (19399)
Vaccines (693)
Weight loss (257)
Date
Today (11)
Last 7 days (632)
Last 30 days (2645)
Last 365 days (36435)
2025 (4720)
2024 (37309)
2023 (42074)
2022 (53380)
2021 (58050)
2020 (56802)
2019 (50097)
2018 (37941)
2017 (35109)
2016 (35048)
2015 (41124)
2014 (35331)
2013 (30699)
2012 (32649)
2011 (33128)
2010 (31429)
Location
Africa (948)
Arizona (229)
Asia (44139)
Australia (7772)
California (4956)
Canada (1745)
China (413)
Colorado (226)
Connecticut (250)
Europe (97263)
Florida (701)
Georgia (168)
Illinois (504)
Indiana (275)
Maryland (794)
Massachusetts (3823)
Michigan (206)
Minnesota (353)
New Jersey (1398)
New York (1401)
North Carolina (942)
Northern California (2140)
Ohio (177)
Pennsylvania (1123)
South America (1333)
Southern California (1845)
Texas (729)
Utah (149)
Washington State (496)
759,714 Results for "melinta therapeutics formerly known as rib x pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Press Releases
Melinta Therapeutics Announces IDWeek 2024 Presentations Focused on Melinta’s Portfolio of Commercial and Investigational Stage Products
October 17, 2024
·
3 min read
Press Releases
Melinta Joins NHIA Future of Infusion Advisory Council
December 2, 2024
·
3 min read
Drug Development
Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris
Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris.
May 23, 2024
·
4 min read
Pharm Country
Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam
Venatorx Pharmaceuticals (Venatorx) and Melinta Therapeutics (Melinta) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for cefepime-taniborbactam.
February 23, 2024
·
12 min read
Pharm Country
Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.
Melinta Therapeutics LLC and Venatorx Pharmaceuticals, Inc., announced that they have entered into a License Agreement to facilitate a strategic partnership in the U.S. to commercialize cefepime-taniborbactam, a beta-lactam / beta-lactamase inhibitor combination antibiotic being developed for the treatment of complicated urinary tract infections and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adults.
November 9, 2023
·
13 min read
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
·
2 min read
·
Tristan Manalac
Business
Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial
Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial.
December 5, 2023
·
8 min read
Press Releases
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor
February 3, 2025
·
7 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025
February 7, 2025
·
4 min read
1 of 75,972
Next
